Cirdan Imaging is investing in its future growth within the precision medicine market, creating 46 new jobs over the next four years and undertaking a major multimillion pound R&D project.
Cirdan Imaging is a company specialising in developing medical devices and software that are used in surgery and cancer diagnosis by pathologists and radiologists. The company has established a growing reputation for ‘Ultra’ its laboratory information system and ‘Vividpath its pathology imaging solution that have a growing customer base among many public and private hospital laboratories.
“This R&D project will enable Cirdan to develop new precision medicine product solutions to meet the future need of both existing and new customers.
“Our support is helping this innovative company to scale up quickly. This is part of a strategic focus to support our smaller companies to realise their full potential and become our major employers of the future.”
Invest NI has offered £1.4m in support towards the R&D project and the creation of the 46 jobs, offering an average salary of £33,500. The R&D project is in collaboration with the Northern Ireland’s Molecular Pathology Laboratory (NIMPL) at Queens University Belfast (QUB).
“The new jobs will help us identify new markets and new customers, and our R&D investment will mean we can develop new products and expand our exports especially into the markets of Oceania and North America.The support of Invest NI has been invaluable to allow us to make the necessary scale of investment within the required timescales to allow us to compete effectively in these markets.”